DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.
EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
STUDY
OFFICIAL TITLE
DISEASE
JOURNAL/
CONGRESS
YEAR
DOWNLOAD
OTHER
The impact of excluding nonrandomized studies from systemic reviews in rare diseases: "The example of meta-analyses evaluating the efficacy and safety of enzyme replacement therapy in patients with mucopolysaccharidosis"
RARE DISEASES
(Journal) Frontiers in Molecular Biosciences
2021
OTHER
PI3K activation promotes resistance to eribulinin HER2-negative breast cancer
BREAST
(Journal) British Journal of Cancer
2021
PHERGAIN
Chemotherapy de-escalation using an ¹⁸F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
BREAST
(Journal) The Lancet
2021
RESPONSE
Predictors of 18F-fluorodexoxyglucose positron-emssion tomography-driven disease detection in pateins with HER2[+] early breast cancer. A substudy of the PHERGAIN trial
BREAST
ESMO Breast
2020
EXCAAPE
223Ra in asymptomatic patients with metastatic castration-resistant prostate cancer (mCRPC) who progressed to first-line abiraterone acetate or enzalutamide: EXCAAPE study
PROSTATE
ESMO
2020
LUPER
Lurbinectedin in combination with Pembrolizumab forpatients with relapsed Small Cell Lung Cancer.LUPER Clinical Trial.
LUNG
IASLC
2020
TRANSFAL
TransFAL: Establishment of clinical trial-matched Patient-Derived Xenografts (PDX) for translational studies
BREAST
ESMO
2020
LUZERN
Effectiveness of niraparib plus aromatase inhibitors (AI) for germinal BRCA 1/2-mutated (gBRCAm) or homologous recombination deficient (HRD), hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2) advanced breast cancer (ABC). The LUZERN strategy
BREAST
ESMO Breast
2020
PHERGAIN
Chemotherapy (CT) De-Escalation using an FDG-PET/CT (PET) and Pathological Response-Adapted Strategy in HER2[+] Early Breast Cancer (EBC). PHERGAIN trial
BREAST
ASCO
2020
OTHER
The value of novelty of case reports in rare disease. The example of a systematic review of case reports evaluating the efficacy and safety of enzyme replacement therapy (ERT) in patients with mucopolysaccharidosis type II (MPS II)
RARE DISEASES
(Journal) International Journal of Environmental Research and Public Health
2020
POLEN
An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study
ENDOMETRIUM
(Journal) Gynecologic Oncology
2020
BIOPER
A phase II proof-of-concept study of palbociclib (P) rechallenge in patients (pts) with hormone receptor (HR)[+]/HER2[-] metastatic breast cancer (MBC) and clinical benefit toprior P-based treatment (BIOPER)
BREAST
SABCS
2020
Other MEDSIR related articles
